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Objectives: Plasmid-mediated AmpC b-lactamases (PMABLs) and carbapene-
mases are emerging groups of antimicrobial-resistance determinants. The aims
of the study were to evaluate the occurrence of PMABLs and carbapenemases in
clinical isolates of Klebsiella pneumoniae and compare the test performance of
various phenotypic methods for detection of these enzymes in Iran.
Methods: A total of 100 K. pneumoniae isolates were collected from clinical
specimens obtained in Valiasr Hospital. AmpC production in all isolates was
determined using the AmpC disk test, the cephamycin Hodge test, the AmpC
Etest, and the boronic acid combined-disk test. In addition, carbapenemase
production was determined using the modified Hodge test, the EDTA disk synergy
test, and the boronic acid combined-disk test. The performances of various
phenotypic methods were evaluated by the comparison of their results with
polymerase chain reaction (PCR) method as the gold standard.
Results: Of the 100 isolates, 19 (19%) were demonstrated to harbor the PMABL-
resistance gene by the multiplex PCR method. The PCR result indicated the
presence of carbapenemase genes in 12 isolates. The performance of various
phenotypic tests carried out for detection of carbapenemase-producing isolates
varied widely, ranging in sensitivity from 30% to 100% and in specificity from
90.8% to 100%.
Conclusion: This is the first report of MOX-type AmpC b-lactamase and blaGES in
K. pneumoniae in Iran. A comparison of the phenotypic methods showed that a
combination of cefoxitin plus boronic acid is optimal for detecting plasmid-ted under the terms of the Creative Commons Attribution Non-Commercial License (http://
0) which permits unrestricted non-commercial use, distribution, and reproduction in any
roperly cited.
ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
334 A. Japoni-Nejad, et almediated AmpC enzymes in K. pneumoniae, whereas the implementation of
molecular methods is often complex, requires specially trained personnel, and is
associated with higher costs.1. Introduction
AmpC b-lactamases are clinically important ceph-
alosporinases encoded on the chromosome of many
organisms such as Citrobacter spp., Enterobacter spp.,
Morganella spp., Hafnia spp., and Serratia spp. in
which they mediate resistance to cephalothin, cefazo-
lin, cefoxitin, most penicillins, and all b-lactamase
inhibitor antibiotics except cefepime and imipenem
[1]. AmpC b-lactamase hydrolyzes cephamycins and
its activity is not inhibited by clavulanic acid. These
features distinguish AmpC b-lactamase from
extended-spectrum b-lactamases. Since 1989, plasmid-
mediated AmpC b-lactamases (PMABLs) have been
detected worldwide in the strains of Escherichia coli,
Klebsiella spp., Proteus mirabilis, and Salmonella spp.
This is because transmissible plasmids have acquired
genes for AmpC enzymes, which consequently can
appear in bacteria lacking (e.g., Klebsiella pneumo-
niae) or poorly expressing a chromosomal ampC gene
(e.g., E. coli).
Although many phenotypic tests are available for
AmpC detection, none of these is validated by the
Clinical and Laboratory Standards Institute (CLSI).
Therefore, it is important to develop methods that can
reliably detect PMABLs [2,3]. Significant spread of
carbapenem-resistant K. pneumoniae was observed in
the United States, Europe, and some Asian countries
[4,5]. Spreading of different types of carbapenemases,
such as K. pneumoniae carbapenemase and the New
Delhi metallo-b-lactamase-1, was reported in Iran and
elsewhere [6,7]. Therefore, we evaluated the prevalence
of PMABLs and carbapenemases in Iranain clinical
isolates of K. pneumoniae and compared the perfor-
mance of phenotypic tests for detection of these
enzymes.2. Materials and methods
2.1. Bacterial strains and susceptibility testing
In this cross-sectional study, 100 nonduplicate K.
pneumoniae isolates were collected from clinical spec-
imens obtained in Valiasr Hospital in the central prov-
ince of Iran (MarcheSeptember 2011).
The identification of all isolates was confirmed by
the API 20E system (bioMerieux, Marcy-l’Etoile,
France). Susceptibilities to 21 different antibiotics
(MAST, Bootle, Merseyside, UK) were defined by disk
diffusion according to the CLSI guidelines (Figure 1)
[8].2.2. Polymerase chain reaction for detecting
PMABLs and carbapenemases genes
DNA extraction was performed based on the method
described by Pe´rez-Pe´rez and Hanson [9]. Polymerase
chain reaction (PCR) was used for amplification of
genes encoding PMABLs (blaMOX, blaCIT, blaDHA,
blaACC, blaEBC, and blaFOX), Ambler class A (blaKPC
and blaGES), metallo-b-lactamases (MBLs; blaIMP, bla-
VIM, blaNDM, blaSPM, blaSIM, and blaGIM), and class D
carbapenemase (blaOXA48) [9e11]. PCR products were
sequenced and analyzed by the Basic Local Alignment
Search Tool algorithm (http://blast.ncbi.nlm.nih.gov/
Blast.cgi).
2.3. Phenotypic detection of PMABLs and
carbapenemases
AmpC production in all isolates was determined by
the following: AmpC Etest (Figure 2B), cephamycin
Hodge test (CHT; Figure 2C), AmpC disk test (Figures
2E and 2F), and combination-disk test with boronic acid
(Figure 2H) [12e14]. In addition, carbapenemase pro-
duction was determined using the following: modified
Hodge test (MHT; Figure 2D), MBL Etest (Figure 2A),
EDTA disk synergy (EDS) testing (Figure 2I), and
combination-disk testing with boronic acid (Figure 2G).
The performances of these test methods were compared
with PCR as the gold standard [15e17].3. Results
Clinical samples were from surgical wounds
(n Z 36; 36%), urines (n Z 41; 41%), blood (n Z 13;
13%), and respiratory secretions (n Z 10; 10%) ob-
tained in surgery and neurology and neurosurgery
intensive care units. Antimicrobial resistances of the
isolates are shown in Figure 1.
Of the 100 isolates tested, 19 (19%) harbored
PMABLs as shown by multiplex PCR; of these 19 iso-
lates, eight (42.2%) carried bla genes of the CIT group
(CMY-2 genes), seven (36.8%) carried genes of the
MOX group, whereas three (15.7%) and one (5.2%)
carried genes belonging to the EBC and DHA groups
(DHA-1; Table 1), respectively.
The PCR result showed that of the 100 isolates, 12
(12%) carried a carbapenemase gene, the most common
being blaVIM (n Z 10, 10%) and blaGES (n Z 2; 2%).
One isolate (1%) contained both blaVIM and blaAmpC
(CIT group; Table 2), whereas blaFOX, blaACC, blaIMP,
blaSIM, blaNDM, blaGIM, blaSPM, blaKPC, and blaOXA48
were not detected in our isolates.
Figure 1. Resistance percent of isolates to the 21 antibiotics used in this study. AK Z amikacin;
AMOeCLAZ amoxicillineclavulanic acid; AZZ aztreonam; CAZZ ceftazidime; CIPZ ciprofloxacin; CMDZ cefamandole;
COL Z colistin; CRO Z ceftriaxone; CT Z cefotetan; CTX Z cefotaxime; E Z erythromycin; FEP Z cefepime;
FOX Z cefoxitin; GM Z gentamicin; IMI Z imipenem; LEV Z levofloxacin; MEM Z meropenem;
PT Z piperacillinetazobactam; RIP Z rifampicin; T Z tetracycline; TS Z trimethoprim/sulfamethoxazole.
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AmpC-producing isolates showed 100% (n Z 19)
resistance to rifampicin and erythromycin; 79%
(n Z 15) to cefamandole, ceftazidime, and cefotaxime;
73.6% (n Z 14) to tetracycline, ceftriaxone, and
aztreonam; 68.5% (n Z 13) to piperacillinetazobactam
and amoxicillineclavulanic acid; 63% (n Z 12) to
cefoxitin; 57.8% (nZ 11) to cefepime; 52.6% (nZ 10)
to cefotetan, ciprofloxacin, levofloxacin, gentamicin,
and trimethoprim/sulfamethoxazole; 31.5% (n Z 6) to
amikacin; 5.2% (n Z 1) to imipenem and meropenem.
None of the isolates was resistant to colistin in this
study.
The results of phenotypic methods for detection of
AmpC- and carbapenemase-producing isolates are
shown in Tables 1 and 2, respectively.
All carbapenemase-producing isolates were resistant
to rifampicin, erythromycin, ciprofloxacin, aztreonam,
meropenem, piperacillinetazobactam, amox-
icillineclavulanic acid, cefamandole, ceftazidime,
cefoxitin, cefotaxime, and ceftriaxone. The frequency of
resistance is as follows: 11/12 (91.6%) to tetracycline
and amikacin; 10/12 (83.3%) to trimethoprim/sulfa-
methoxazole, gentamicin, and levofloxacin; 9/12 (75%)
to cefotetan; and 8/12 (66.6%) to imipenem. The most
effective antimicrobial agent against carbapenemase-
producing K. pneumoniae in this study was colistin with
100% susceptibility. Eight of the 12 carbapenemase-
producing isolates were AmpC positive in the MHT;
AmpC was not detected in the other four isolates. Five
noncarbapenemase-producing isolates were falsely pos-
itive in MHT. Of these five isolates, four were AmpC
producers.4. Discussion
The prevalence of PMABLs evaluated in this study
(19%) is much higher than described in several other
parts of the world. In an earlier study from Iran, the
prevalence of PMABLs was 8.4% in K. pneumoniae. In
Japan, the prevalence of PMABLs was 13% in K.
pneumoniae [18]. In China, the rate was 10.1% in K.
pneumoniae and the lowest rates of AmpC genes were
reported from Switzerland (0.4%) [19]. High prevalence
of AmpC genes was reported from Korea (77%) and
Singapore (26%) [19]. In this study, similar to other
reports, CIT- (CMY-2) and MOX-type genes were pre-
dominantly present in K. pneumoniae, followed by the
EBC and DHA types, whereas the ACC and FOX genes
were not detected. The CMY-2 is one of the most
prevalent and most widely distributed PMABLs and has
been previously found in several countries [1].
The rate of resistance to cefoxitin in our isolates was
46% (n Z 46); only 12 isolates were AmpC producers
and 34 isolates were negative. Cefoxitin resistance in
these nonproducers could be due to some other resis-
tance mechanism such as alterations in outer membrane
permeability [2,20]. In this study, 63% (12/19 isolates)
and 68.4% (13/19) of AmpC producers were found to be
resistant to cefoxitin and amoxicillineclavulanic acid,
respectively.
Cefotetan has a lower sensitivity than cefoxitin con-
cerning the detection of AmpC production (52.6% vs.
63%). These data indicate that although screening
methods using cefoxitin and amoxicillineclavulanic
acid for detection of AmpC-harboring isolates are use-
ful, they are not perfect [20,21]. Therefore, in contrast to
Figure 2. Results of the phenotypic methods for detection of plasmid-mediated AmpC and carbapenemase enzymes in Klebsiella
pneumoniae isolates. (A) MBL-positive isolate, (B) AmpC Etest, inconclusive result in isolate, (C) cephamycin Hodge test (CHT),
AmpC-negative and AmpC-positive isolates, (D) modified Hodge test (MHT), (E and F) AmpC-negative and AmpC-positive
isolates, (G) a positive result obtained from blaGES using the imipenem þ boronic acid disk test (top) and a positive result ob-
tained from AmpC using the cefoxitin þ boronic acid disk test (bottom), (H) cefoxitin þ boronic acid disk test (positive isolate), (I)
positive result obtained from MBL-producer isolate using the EDTA disk synergy (EDS) test. BA Z boronic acid;
CHT Z cephamycin Hodge test; FOX Z cefoxitin; IMI Z imipenem; MBL Z metallo-b-lactamase; MHT Z modified Hodge
test; Ne Z negative; Po Z positive.
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itin, cefotetan, and amoxicillineclavulanic-acid-sus-
ceptibility testing for initial AmpC screening.
Resistance to cefepime among 11/19 (58%) AmpC-
positive K. pneumoniae isolates is another important
finding. No synergy was found between expanded-
spectrum cephalosporins and clavulanic acid using the
double-disk synergy test (data not shown). Only 1/11
cefepime-resistant isolates in this study had carbapene-
mase genes (blaVIM) and thus, resistance to cefepime
may be mediated by structurally modified AmpC b-
lactamases [23].
We found that the cefoxitin  boronic acid disk test
detected 19/19 AmpC-positive K. pneumoniae isolates
and gave one false-positive result. The AmpC disk test
and CHT detected 7/19 and 5/19 AmpC-positive strains
(12 and 14 false negatives), respectively. Possibly,
inhibitory compounds exhibit different levels of inhibi-
tion among heterogeneous groups of AmpCs [24].
The AmpC disk test and CHT gave five false-positive
results. Of these five isolates, three were MBL (blaVIM)
producers and the two others were blaGES positive.
The AmpC Etest was easy to use, but was unsuitable
for AmpC detection. Overall, 17/19 AmpC-producingisolates were not detected by this method. Test perfor-
mance could be improved by developing an Etest strip
with a broader minimum inhibitory concentration range.
Inconclusive results using this test have been previously
reported [21,22]. However, we indicate that
combination-disk testing with boronic acid is potentially
useful for clinical laboratories for the detection of
PMABLs [13].
The prevalence of carbapenemases among our iso-
lates was found to be 12%. The sensitivity and speci-
ficity of disk diffusion for their identification using
imipenem disk were 66.6% and 100%, respectively,
whereas meropenem disk demonstrated 100% sensitivity
and specificity. Apparently, application of meropenem
disk is superior for screening, which is in contrast to the
study carried out by Benenson et al [25].
This is the first report of blaGES and blaMOX in Iran.
Guiana extended-spectrum b-lactamase (GES b-lacta-
mase) has been reported in Europe [26]. In our region,
carbapenem resistance has emerged in K. pneumoniae,
mostly as VIM-type MBLs. VIM-MBL producers have
been reported in Greece, Kuwait, and Korea [27].
Four VIM-producing isolates were not detected by
MHT (Table 2). It has been suggested that addition of
Table 1. Characteristics of the 19 AmpC-positive isolates in this study.a
No. of
isolates
AmpC
group
Cephalosporin
phenotype
AmpC
disk test
Cephamycin
Hodge
test
AmpC
Etest
Cefoxitin/cefoxitin
þ boronic
acidCAZ CTX FOX CT FEP
5 CIT S S S S S    þ
7 CIT S S S S S    þ
9 MOX R R R R R   IR þ
11 MOX R R R R R þ  IR þ
12 MOX R R R R R   IR þ
17 MOX R R R R R   þ þ
1 MOX R R S S R    þ
21 MOX S S S S S    þ
22 MOX R R R S S þ þ  þ
3 DHA R R R R S þ  IR þ
6 EBC S S S S S    þ
51 EBC R R S S R    þ
49 CIT R R S S R    þ
55 CIT R R R R R þ þ IR þ
60 CIT R R R S R þ þ  þ
68 CIT R R R R R   IR þ
75 CIT R R R R S þ þ IR þ
89 CIT R R R R R   IR þ
27 EBC R R R R S þ þ þ þ
aResults were rated inconclusive if the minimum inhibitory concentrations exceeded the scale of the Etest for cefotetan alone and/or cefotetan in combination
with cloxacillin (Etest AmpC). CAZ Z ceftazidime; CT Z cefotetan; CTX Z cefotaxime; FEP Z cefepime; FOX Z cefoxitin; IMI Z imipenem;
IR Z inconclusive result.
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the sensitivity of the MHT for MBL producers [28]. In
addition, the MHT gave five false positives. The overall
sensitivity and specificity of the MHT were 66% and
94.3%, respectively. The sensitivity and specificity of
the imipenem  boronic acid disk test were 100% and
90.8%, respectively.
Although two GES-producing isolates were detected
using the MHT, there were also nine false-positive re-
sults. Of these nine isolates, six were MBL (blaVIM)Table 2. Characteristics of 12 carbapenemase-positive isolates
Isolates
Carbapenem phenotype
b-Lactamases
IMI
boroIMI MEM
15 R R VIM þ
18 R R VIM þ
20 R R VIM 
39 S R VIM þ
43 S R VIM 
47 S R VIM 
55 R R VIM and CIT þ
69 S R VIM þ
70 R R VIM þ
74 R R VIM þ
23 R R GES þ
73 R R GES þ
aWeakly positive. CAZ Z ceftazidime; IMI Z imipenem; MBL Z metallo-b-lproducers and three were AmpC producers. It is possible
that other AmpC families, not detected by the multiplex
PCR, were present in the six VIM-producer isolates in
our study.
The MBL Etest was the most specific test (100%) for
MBL detection in this study. In the EDS test, the
EDTAeceftazidime combination detected additional
MBL producers, which were not identified by the
EDTAeimipenem combination (90% sensitivity vs.
30% sensitivity). Therefore, ceftazidime appears to bein this study.
/IMI þ
nic acid MHT
IMI/IMI
þ EDTA
CAZ/CAZ
þ EDTA MBL Etest
 þ þ þ
þ þ þ þ
 þ þ þ
þa  þ þ
  þ þ
  þ þ
þ   
þ  þ þ
þ  þ þ
þ  þ þ
þ þ þ 
þ þ þ 
actamases; MEM Z meropenem; MHT Z modified Hodge test.
338 A. Japoni-Nejad, et althe better substrate for the EDS test. Similar results were
observed by Noyal et al [29].
In conclusion, this study confirmed the prevalence of
AmpC-producing K. pneumoniae and carbapenemase
(blaVIM and blaGES) in the central hospital of Arak (Iran)
to be very high. By understanding the resistance pattern
and prevalence of the b-lactamase-producing organisms,
especially K. pneumoniae, we would be able to manage
infection-control policy as well as proper and rational
antibiotics prescription. The results indicate that a
cefoxitin plus boronic acid is potential method for clinical
laboratories to detect emerging AmpC-plasmid-mediated
enzymes in K. pneumoniae, whereas the implementation
of molecular methods is often complex, requires specially
trained personnel, and is associated with higher costs.Conflicts of interest
The authors declare no conflicts of interest.
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